Inhaled iloprost did not influence cytokines levels in patients with different forms of pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Inhaled iloprost in HIV-related pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004
Effects of long-acting inhaled β-adrenergic and anticholinergic drugs on respiratory function and arterial blood gases in patients with COPD Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006
Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016
The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Inhaled iloprost reverses chronic experimental pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 353s Year: 2005
Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015
Inhaled iloprost for the treatment of pulmonary hypertension Source: Eur Respir Rev 2009; 18: 29-34 Year: 2009
Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 8-13 Year: 2001
Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013
The influence of statin supplementation on inflammatory markers in patients with chronic obstructive pulmonary disease Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015
Inhaled treprostinil therapy in patients with pulmonary hypertension and parenchymal lung disease Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma Source: Eur Respir J 2006; 27: 172-187 Year: 2006
Inhaled INS1009 demonstrates localized pulmonary vasodilation activity Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016
Effects of nebulised iloprost on pulmonary function and oxygenation in patients with severe pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002
Inhaled iloprost for patients with pulmonary arterial hypertension and right heart failure Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010
Smoking, systemic inflammation and pulmonary function Source: Eur Respir J 2006; 28: Suppl. 50, 248s Year: 2006
Pulmonary function in smoking and systemic inflammation Source: Annual Congress 2009 - Tobacco: from smoke to disease Year: 2009
Pulmonary hypertension: future therapies Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=84 Year: 2004
Phosphodiesterase inhibitors as promising therapies for cigarette smoke-induced emphysema and pulmonary hypertension (PH) in mice Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014